Previously, Plexico was director of business development of Chemdex Corporation and before that he was national sales manager for Quidel Corporation’s autoimmune & complement division. Plexico earned a Bachelor of Arts degree in political science from Colgate University.

“Jon brings to Zila’s board of directors a broad perspective, gained as a professional money manager, investment banker and healthcare executive,” said David Bethune, Zila’s chairman and chief executive officer. “As a long-term shareholder of Zila, he supports the company’s strategy and has a keen understanding of its needs. We welcome Jon and look forward to his insights as we work through our financial challenges.”

“Stonepine Capital has been a supportive Zila shareholder during its restructuring over the past year,” said Plexico. “We are strong believers in the company’s oral cancer screening product, ViziLite® Plus, and trust it not only has excellent growth potential but, most importantly, can help save lives. I’m personally delighted to be working with the entire board and management team to help advance this mission.”